What is HC Wainwright’s Estimate for AUTL FY2025 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Investment analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Autolus Therapeutics in a report issued on Tuesday, February 17th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.04) per share for the year. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.64) EPS and FY2030 earnings at ($0.24) EPS.

A number of other research analysts also recently issued reports on AUTL. Zacks Research downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Needham & Company LLC cut their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.51 on Wednesday. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The company has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $1.57. The company has a market cap of $401.87 million, a PE ratio of -1.82 and a beta of 1.98.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in AUTL. Armistice Capital LLC boosted its position in shares of Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after buying an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd raised its stake in Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares in the last quarter. Cetera Investment Advisers boosted its position in Autolus Therapeutics by 17.6% during the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after acquiring an additional 92,300 shares during the period. R Squared Ltd bought a new position in shares of Autolus Therapeutics in the second quarter worth $50,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Autolus Therapeutics in the second quarter worth $1,288,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.